Shionogi's Fetroja Receives FDA Approval, Poised to Capture Market Share in Multi-Drug Resistant Gram-Negative Bacteria Treatment
Innovative Antibiotic Fetroja Approved by FDA
Shionogi's Fetroja (cefiderocol) is the first siderophore cephalosporin antibiotic utilizing a unique 'Trojan horse' mechanism that employs an iron transport system. The FDA initially approved Fetroja on November 14, 2019, for the treatment of complicated urinary tract infections (cUTI). On September 27, 2020, the FDA expanded its approval to include hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). This provides a critical alternative for patients infected with Gram-negative bacteria resistant to existing treatments, representing a significant clinical advancement.
Differentiated Therapeutic Efficacy Demonstrated Through Clinical Trials
The regulatory approval of Fetroja is based on the results of the large-scale Phase 3 clinical trials, APEKS-NP and CREDIBLE-CR. In particular, the CREDIBLE-CR trial, which involved patients with carbapenem-resistant Gram-negative bacteria (CRGNB) infections, demonstrated non-inferior efficacy compared to the best available therapy (BAT). These results offer new hope for critically ill patients suffering from multi-drug resistant (MDR) pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Rising Sales Driven by Growth in the Multi-Drug Resistant Market
The global market for antimicrobial resistance (AMR) and multi-drug resistant Gram-negative bacteria treatments is estimated at approximately USD 12.4 billion in 2025 and is projected to grow to USD 24.8 billion by 2035. Shionogi is successfully pursuing the global commercialization of Fetroja to meet this demand, achieving strong sales growth. Fetroja's US sales surged from 14.5 billion yen in 2023 to 20 billion yen in 2024, and European sales also increased from 10.7 billion yen to 12.9 billion yen, establishing it as a key growth driver.
Market Competition and Innovative Business Model
Fetroja competes with strong competitors in the market, such as Avycaz from Pfizer and Vabomere from Melinta. Shionogi is demonstrating strategic flexibility by going beyond simple sales competition, such as adopting a subscription-based (Netflix-style) health insurance pricing model in the UK or entering into a licensing agreement with the Global Antimicrobial Resistance and Use Surveillance System (GARDP) to ensure access for patients in developing countries. This multifaceted market entry strategy is considered a valuable benchmark for securing stable revenue streams within a long-term antimicrobial stewardship framework.
Fetroja has secured FDA approval following Phase 3 clinical trials APEKS-NP and CREDIBLE-CR, establishing itself as a definitive treatment standard in the area of multi-drug resistant (MDR) Gram-negative bacteria. The global market for multi-drug resistant Gram-negative bacteria, estimated at USD 12.4 billion in 2025, is projected to grow steadily to USD 24.8 billion by 2035, indicating that the commercial value of innovative antibiotics will continue to rise. Shionogi has demonstrated strong sales growth in the US and European markets, with revenues of 20 billion yen and 12.9 billion yen, respectively, in 2024, intensifying competition with existing players such as Pfizer's Avycaz. The introduction of innovative pricing models, such as the subscription-based payment system in the UK, provides a sustainable commercialization roadmap for the antibiotic industry, which has seen limited new drug development. The establishment of a stable supply chain for multi-drug resistant treatments and the resolution of unmet clinical needs are expected to significantly enhance Shionogi's long-term corporate value and attractiveness as a biopharmaceutical investment.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA209445